UK markets closed
  • FTSE 100

    7,765.15
    +4.04 (+0.05%)
     
  • FTSE 250

    20,035.39
    +119.88 (+0.60%)
     
  • AIM

    869.24
    +3.83 (+0.44%)
     
  • GBP/EUR

    1.1403
    +0.0014 (+0.12%)
     
  • GBP/USD

    1.2395
    -0.0012 (-0.10%)
     
  • BTC-GBP

    18,575.43
    -77.26 (-0.41%)
     
  • CMC Crypto 200

    526.66
    +9.65 (+1.87%)
     
  • S&P 500

    4,070.56
    +10.13 (+0.25%)
     
  • DOW

    33,978.08
    +28.67 (+0.08%)
     
  • CRUDE OIL

    79.38
    -1.63 (-2.01%)
     
  • GOLD FUTURES

    1,927.60
    -2.40 (-0.12%)
     
  • NIKKEI 225

    27,382.56
    +19.81 (+0.07%)
     
  • HANG SENG

    22,688.90
    +122.12 (+0.54%)
     
  • DAX

    15,150.03
    +17.18 (+0.11%)
     
  • CAC 40

    7,097.21
    +1.22 (+0.02%)
     

Views of 258 Neurology Patient Groups on the Corporate Reputation of Pharma in 2022: Roche Ranked 1st, Novartis Ranked 2nd and Biogen Ranked 3rd

Company Logo
Company Logo

Neurology Company Pharma Rankings

Neurology Company Pharma Rankings
Neurology Company Pharma Rankings

Dublin, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2022 - The Patient Perspective - Neurology Edition: The Views of 258 Neurology Patient Groups" report has been added to ResearchAndMarkets.com's offering.

The 'Corporate Reputation of Pharma' survey - Neurology edition, is now in its 9th year. Between November 2021-February 2022, the survey collected the opinions of 258 neurology patient groups on the performance of the pharmaceutical industry during 2021.

Patient groups - and neurology patient groups especially - possess a deep and unique understanding of the patients they represent, and express the collated views of these patients. Patient-group perspectives have become increasingly important to regulators that demand patient input into trial design and conduct (as well as into the evaluation of clinical outcomes).

At the same time, many patient groups are also familiar with the complexities of the pharmaceutical industry's business. From their vantage point, therefore, patient groups are both able to assess pharma, and to recommend ways in which companies can improve - all from a patient perspective.

The report provides details on:

  • How the analyst measures pharma's corporate reputation from a patient perspective;

  • The companies included in the 2021 neurology analyses;

  • The headline results of the 2021 survey, from the perspective of neurology patient groups; and

  • The profiles of 2021's respondent neurology patient groups.

COMPANY RANKINGS IN THE FIELD OF NEUROLOGICAL CONDITIONS, 2021

  • The top-three pharma companies out of 20 companies, ranked for their overall corporate reputation in 2021, as assessed by respondent neurology patient groups familiar with the company: Roche, 1st - Novartis, 2nd - Biogen, 3rd.

  • The top-three pharma companies out of 12 companies, ranked for their overall corporate reputation in 2021, as assessed by respondent neurology patient groups working with the company: Roche, 1st - Novartis, 2nd - Pfizer, 3rd.

  • The top-three 'big-pharma' companies out of 11 companies, ranked for their overall corporate reputation in 2021, assessed by respondent neurology patient groups familiar with the company: Roche, 1st - Novartis, 2nd - Pfizer, 3rd.

  • The top-three 'big-pharma' pharma companies out of 6 companies, ranked for their overall corporate reputation in 2021, assessed by respondent neurology patient groups working with the company: Roche, 1st - Novartis, 2nd - Pfizer, 3rd.

Key Topics Covered:

  • Executive summary

  • Relationships that neurological patient groups have with pharma, 2021

  • Industry-wide findings, according to respondent neurological patient groups, 2021

  • Rankings of 20 pharma companies, 2021 v. 2020, as assessed by respondent neurological patient groups familiar with the companies

  • Rankings of 12 pharma companies, 2021 v. 2020, as assessed by respondent neurological patient groups working with the companies

  • Rankings of 11 'big-pharma' companies, 2021 v. 2020, as assessed by respondent neurological patient groups familiar with the companies

  • Rankings of 6 'big-pharma' companies in Neurological, 2021 v. 2020, as assessed by respondent neurological patient groups working with the companies

  • Profiles of the 20 companies, 2021 (v. 2020)

Appendices

I. Profiles of respondent neurological patient groups, 2021
II. List of respondent neurological patient groups that wished to be attributed, 2021
III. Commentaries and feedback from respondent neurological patient groups on how pharma can improve, 2021-2022
IV. The 'Corporate Reputation of Pharma, 2021-Multiple-Sclerosis edition'

Profiles of the 20 companies, 2021

  • AbbVie

  • AstraZeneca

  • Bayer

  • Biogen

  • Boehringer Ingelheim

  • Bristol Myers Squibb

  • Eisai

  • Eli Lilly

  • Grunenthal

  • GSK

  • Janssen

  • Lundbeck

  • Merck KGaA/EMD Serono

  • Novartis

  • Pfizer

  • Roche/Genentech/Chugai

  • Sanofi

  • Takeda

  • Teva

  • UCB

Each company is profiled by the following measures:

  • The number of respondent neurological patient groups familiar, and working, with the company, 2021.

  • The profile of the respondent neurological patient groups familiar with the company(the number of patients reached; country headquarters; specialties; and geographic remit), 2021.

  • The types of relationships that the company had with its respondent neurological patient-group partners, 2021.

  • Company performance at the individual indicators of corporate reputation in 2021 - as assessed by respondent neurological patient groups familiar, and working, with the company.

  • Competitors' relationships in 2021 with the company's respondent neurological patientgroup partners.

  • Overall rankings for the company-as assessed by respondent neurological patient groups familiar, and working, with the company, 2021 v. 2020.

  • Company rankings for each of the indicators-as assessed by respondent neurological patient groups familiar, and working, with the company, 2021 v. 2020.

  • Snapshot view: where the company sits in the corporate tiers for each of the indicators(in the higher, the middle, or the lower tier)-as assessed by respondent neurological patient groups familiar, and working, with the company, 2021.

  • Overall rankings of the company, 2015-2021-expressed on the Patient Corporate

  • Reputation Index (PCRI), a measure designed to standardise the analyst's ranking data (preventing results being skewed by the differing numbers of companies included in the neurological historic analyses over the various years). PCRI ranking is from 0 to 1, with 1 being the best (the highest rank)-as assessed by respondent neurological patient groups familiar with the company.

For more information about this report visit https://www.researchandmarkets.com/r/is5rct

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900